Aerocrine applies for delisting

The Board of Directors of Aerocrine AB (publ) (“Aerocrine”) has decided to apply
for the delisting of the Aerocrine share from Nasdaq Stockholm. The last day of
trading in the share is expected to be July 13, 2015.
On June 15, 2015, Circassia Pharmaceuticals plc (“Circassia”) announced that the
public offer to the shareholders of Aerocrine had been accepted to such an
extent that Circassia now holds 92.6 percent of the shares and votes in
Aerocrine. Circassia also announced its intention to request compulsory buy-out
(tvångsinlösen) of the remaining shares in Aerocrine. In light of this,
Aerocrine’s Board of Directors concludes that it is no longer justified for the
company to remain listed and therefore has resolved to apply for the delisting
of the Aerocrine share from Nasdaq Stockholm. The last day of trading in the
Aerocrine share on Nasdaq Stockholm is expected to be July 13, 2015.

For more information, contact:

Jenny Rosberg, IR/PR, ROPA, Phone +46 70 747 27 41

Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336

Marshall Woodworth, Chief Financial Officer, Aerocrine AB, Phone: +1 919 749
8748

About Aerocrine
Aerocrine AB is a medical products company focused on improved management and
care of patients with inflammatory airway diseases such as asthma. Within this
sector, Aerocrine is the world leader. Aerocrine markets NIOX MINO® which
enables fast and reliable point-of-care measurement of airway inflammation. This
product plays a critical role in more effective diagnosis, treatment and follow
-up of patients affected with inflammatory airway diseases. Aerocrine is based
in Sweden with subsidiaries in the US, Germany, Switzerland and the UK.
Aerocrine shares have been listed on the Stockholm Stock Exchange since 2007
(AERO-B.ST). For more information please visit www.aerocrine.com and
www.niox.com.

Aerocrine is required to disclose the information provided herein pursuant to
the Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 3:45 pm CET June 26, 2015.